Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in equally subcutaneous as well as oral dosage kind (to start with authorized oral GLP-1 receptor agonist). It has been accepted like a 2nd line treatment method option for far better glycaemic Regulate in f